Pediatric diabetes medications

Early treatment with the anti-CD3 monoclonal antibody teplizumab may help to preserve β-cell function in children and adolescents with newly diagnosed type 1 diabetes, results of the phase 3 PROTECT study show.

Empagliflozin, but not linagliptin, provides “clinically relevant” improvements in glycemic control versus placebo in children and adolescents with type 2 diabetes, report the DINAMO investigators.

Read more about this decision here

Click through to read more on this announcement

Click through to read more on this announcement

Semaglutide at a dose of 2.4 mg/week results in substantial weight loss among adolescents with obesity, show the results of the STEP TEENS trial.

Among adolescents with type 1 diabetes, those with better self-care are more likely to have favorable glycated hemoglobin trajectories into early adulthood, study findings suggest.

Ultra-rapid lispro gives equivalent overall glycemic control to standard lispro, and is significantly better for some postprandial measurements in children with type 1 diabetes, shows the PRONTO-Peds trial.

Dulaglutide delivers significant reductions in glucose levels for youths with type 2 diabetes, report the AWARD-PEDS investigators.

The first phase 3 trial of an SGLT2 inhibitor in children and young people with type 2 diabetes shows that dapagliflozin significantly improves their glucose control – as long as they remember to take it.

Using a linear insulin to carbohydrate ratio to determine breakfast insulin requirements leads to significant differences in time in glycemic range and hypoglycemia rates when meal carbohydrate quantities vary, shows a study in children and young adults.

Click through for more information on this expanded indication

The Omnipod 5 tubeless automated insulin delivery system improves glycemic outcomes of very young children with type 1 diabetes and the sleep of their caregivers, report researchers.

Dasiglucagon, a next-generation glucagon analog in a ready-to-use formulation, rapidly restores plasma glucose levels following severe hypoglycemia in children and adolescents with type 1 diabetes, show findings from a phase 3 trial.

Click through to read more on this announcement

Click through to read more on this announcement

Children and adolescents with type 1 diabetes become more diligent about bolusing for insulin at mealtimes in the run-up to a clinic appointment, as reflected in objective data from their insulin pumps.

Findings from the EDITION JUNIOR trial indicate that glargine-300 and glargine-100 have similar efficacy and safety when used with mealtime insulin in children and adolescents with type 1 diabetes.

Liraglutide 3.0 mg boosts weight loss in obese adolescents receiving lifestyle therapy, show the findings of a phase 3 trial.

The failure of intensive medication to halt beta-cell decline in children with early type 2 diabetes occurs despite them having better baseline beta-cell and alpha-cell function than newly diagnosed adults, say the RISE researchers.